CN112351775A - 用于改善血糖控制和治疗炎性肠病的结构修饰的脂肪酸 - Google Patents

用于改善血糖控制和治疗炎性肠病的结构修饰的脂肪酸 Download PDF

Info

Publication number
CN112351775A
CN112351775A CN201980034666.XA CN201980034666A CN112351775A CN 112351775 A CN112351775 A CN 112351775A CN 201980034666 A CN201980034666 A CN 201980034666A CN 112351775 A CN112351775 A CN 112351775A
Authority
CN
China
Prior art keywords
compound
groups
formula
ibd
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980034666.XA
Other languages
English (en)
Chinese (zh)
Inventor
D.A.弗拉瑟
T.斯克杰雷特
D.舒潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Beihai Medical Private Ltd
Original Assignee
BASF SE
Beihai Medical Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE, Beihai Medical Private Ltd filed Critical BASF SE
Publication of CN112351775A publication Critical patent/CN112351775A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980034666.XA 2018-05-23 2019-05-22 用于改善血糖控制和治疗炎性肠病的结构修饰的脂肪酸 Pending CN112351775A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180714 2018-05-23
NO20180714 2018-05-23
PCT/IB2019/000655 WO2019224602A2 (en) 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CN112351775A true CN112351775A (zh) 2021-02-09

Family

ID=67688797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034666.XA Pending CN112351775A (zh) 2018-05-23 2019-05-22 用于改善血糖控制和治疗炎性肠病的结构修饰的脂肪酸

Country Status (8)

Country Link
US (2) US20210290576A1 (enExample)
EP (1) EP3796901A2 (enExample)
JP (1) JP7508447B2 (enExample)
KR (2) KR20210015883A (enExample)
CN (1) CN112351775A (enExample)
AU (1) AU2019274203B2 (enExample)
CA (1) CA3101041A1 (enExample)
WO (1) WO2019224602A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102760537B1 (ko) 2022-01-20 2025-02-03 한국과학기술연구원 삼원계 광활성층 조성물 및 이를 포함하는 유기태양전지

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159200A (zh) * 2008-07-15 2011-08-17 普罗诺瓦生物医药挪威公司 用作食品补充剂或药物的新的含硫脂质
CN102459142A (zh) * 2009-05-08 2012-05-16 普罗诺瓦生物医药挪威公司 用于治疗与心血管、代谢和炎性疾病领域相关的疾病的多不饱和脂肪酸
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
TW201138832A (en) 2010-01-20 2011-11-16 Pronova Biopharma Norge As Salicylate fatty acid derivatives
WO2014132135A2 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
WO2016156912A1 (en) 2015-04-01 2016-10-06 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
AU2016256552B2 (en) * 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159200A (zh) * 2008-07-15 2011-08-17 普罗诺瓦生物医药挪威公司 用作食品补充剂或药物的新的含硫脂质
CN102459142A (zh) * 2009-05-08 2012-05-16 普罗诺瓦生物医药挪威公司 用于治疗与心血管、代谢和炎性疾病领域相关的疾病的多不饱和脂肪酸
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEETHA VANI RAYASAM等: "Fatty acid receptors as new therapeutic targets for diabetes", vol. 11, no. 5, pages 661 - 671, XP009089705 *
MARIKO MORISHITA等: "Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion", vol. 132, no. 2, pages 99 - 104, XP025684665, DOI: 10.1016/j.jconrel.2008.09.001 *

Also Published As

Publication number Publication date
KR20250150676A (ko) 2025-10-20
KR20210015883A (ko) 2021-02-10
WO2019224602A2 (en) 2019-11-28
CA3101041A1 (en) 2019-11-28
US20210290576A1 (en) 2021-09-23
JP2021526552A (ja) 2021-10-07
AU2019274203B2 (en) 2025-01-02
AU2019274203A1 (en) 2021-01-07
EP3796901A2 (en) 2021-03-31
JP7508447B2 (ja) 2024-07-01
WO2019224602A3 (en) 2020-03-05
US20260000632A1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7313405B2 (ja) 線維症の治療
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP2022169806A (ja) Ａｃｃ阻害剤を含む併用療法
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
TW201733582A (zh) Fxr促效劑及arb之組合醫藥
TW201322977A (zh) 合成的三□系化合物及其使用於治療疾病之方法
CN115969802A (zh) 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途
US20200352890A1 (en) Reversibly protected thiolated electrophilic fatty acids as prodrugs
CN103702668A (zh) 治疗糖尿病的组合物和方法
JP2017508817A (ja) 肝内胆汁うっ滞症の治療
US20260000632A1 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
JP2017536380A (ja) １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
AU2020201980A1 (en) Combination of FXR agonists
JP6915050B2 (ja) Ｆｘｒアゴニストの新規のレジーム
CN114340632A (zh) 用于治疗或预防非酒精性脂肪性肝炎（nash）的药物组合物
US11491128B2 (en) Reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions
TWI906348B (zh) 脂肪性肝疾病之治療劑
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
WO2002017911A1 (en) Parathyroid hormone production inhibitors containing vitamin d3 derivatives
KR20230128307A (ko) 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210209